Stockscreener 앱 받기
3.93
1.75%
-0.07
전일 마감가:
$4.00
열려 있는:
$4.05
하루 거래량:
846.25K
Relative Volume:
0.58
시가총액:
$390.36M
수익:
$58.36M
순이익/손실:
$-25.72M
주가수익비율:
-10.79
EPS:
-0.3641
순현금흐름:
$-24.91M
1주 성능:
-1.01%
1개월 성능:
+20.92%
6개월 성능:
+26.77%
1년 성능:
+2.88%
1일 변동 폭
$3.85
$4.07
1주일 범위
$3.85
$4.30
52주 변동 폭
$2.12
$5.80
Aquestive Therapeutics Inc Stock (AQST) Company Profile
명칭
Aquestive Therapeutics Inc
전화
908-941-1900
주소
30 TECHNOLOGY DRIVE, WARREN, NJ
AQST을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.93 | 397.31M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
151.01 | 67.12B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.32 | 45.19B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.81 | 43.57B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.54 | 18.93B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.56 | 13.45B | 2.99B | 1.21B | 1.13B | 25.06 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-10 | 개시 | Leerink Partners | Outperform |
| 2024-04-11 | 개시 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | Raymond James | Outperform |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2019-04-22 | 개시 | H.C. Wainwright | Buy |
| 2019-01-03 | 개시 | Lake Street | Buy |
| 2018-08-20 | 개시 | JMP Securities | Mkt Outperform |
| 2018-08-20 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Aquestive Therapeutics Inc 주식(AQST)의 최신 뉴스
Published on: 2025-07-29 20:47:23 - beatles.ru
Published on: 2025-07-29 19:03:19 - beatles.ru
Aquestive's Anaphylm to be reviewed by Health Canada - MSN
Published on: 2025-07-29 10:12:06 - metal.it
Published on: 2025-07-29 04:40:45 - metal.it
Investors Hope for Bounce in Aquestive Therapeutics Inc. After SelloffTriple Digit Return Stock Predictions Released - metal.it
Is Aquestive Therapeutics Inc. a growth stock or a value stockSmart Portfolio Recommendation For Beginners - jammulinksnews.com
Why Aquestive Therapeutics Inc. stock attracts strong analyst attentionLow Risk Equity Screener With Results Shared - metal.it
What are the latest earnings results for Aquestive Therapeutics Inc.Rapid market gains - jammulinksnews.com
What makes Aquestive Therapeutics Inc. stock price move sharplyBreakout Stocks Tips For Beginners - jammulinksnews.com
How does Aquestive Therapeutics Inc. generate profit in a changing economyOutperformance with explosive growth - jammulinksnews.com
Should I hold or sell Aquestive Therapeutics Inc. stock in 2025Maximize gains with strategic stock entries - jammulinksnews.com
What are the technical indicators suggesting about Aquestive Therapeutics Inc.Unprecedented profit potential - jammulinksnews.com
What institutional investors are buying Aquestive Therapeutics Inc. stockRemarkably fast returns - jammulinksnews.com
How Efficient Is Aquestive Therapeutics Inc. at Controlling Operating CostsBreakout Confirmation Tool - metal.it
What is the dividend policy of Aquestive Therapeutics Inc. stockUnlock powerful portfolio optimization tools - jammulinksnews.com
How strong is Aquestive Therapeutics Inc. company’s balance sheetAccelerated investment success - jammulinksnews.com
Is Aquestive Therapeutics Inc. a good long term investmentExceptional stock performance - PrintWeekIndia
What drives Aquestive Therapeutics Inc. stock priceDynamic growth stocks - PrintWeekIndia
What analysts say about Aquestive Therapeutics Inc. stock outlookTremendous gains - jammulinksnews.com
Why Aquestive Therapeutics Inc. stock is on top investor watchlistsDynamic capital growth - jammulinksnews.com
Should I buy Aquestive Therapeutics Inc. stock before earningsRapidly growing investment returns - jammulinksnews.com
Aquestive Therapeutics Inc. Stock Analysis and ForecastBreakthrough investment results - PrintWeekIndia
What analysts say about Aquestive Therapeutics Inc. stockAccelerated profit realization - jammulinksnews.com
Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer - GlobeNewswire
EpiPen Veteran to Lead Aquestive's Revolutionary Oral Epinephrine Launch as New Chief Commercial Officer - Stock Titan
After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar - simplywall.st
Aquestive Therapeutics Inc (AQST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.29%
0.41%
자본화:
|
볼륨(24시간):